ASH 2023 Multiple Myeloma Highlights – PERSEUS, IsKia, Bortezomib dosing, KarMMA-3 Update with Dr. Jens Hillengass

Share on facebook
Share on whatsapp
Share on twitter
Share on linkedin

In discussion with Dr. Jens Hillengasss from Roswell Park Comprehensive Cancer Center, covering the Multiple Myeloma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Hillengass:

– PERSEUS – Ph 3 Randomized Study of Dara + Bortezomib + Len + Dex (Dara-VRd) vs VRd Alone in Patients with NDMM Who Are Eligible for Autologous Stem Cell Transplantation (ASCT)

– IsKia – Ph 3 Randomized Study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in NDMM

– Bortezomib Dosing – Retrospective Observational Study on Real-World Bortezomib Prescribing Patterns and Outcomes in NDMM

– KarMMA-3 Update – Idecabtagene Vicleucel (ide-cel) vs Standard Regimens in Patients with Triple-Class–Exposed (TCE) RRMM: Updated Analysis

Subscribe Now


Dr. Rahul

Dr. Rahul is a Chief of Medical Oncology, making up one-half of the ‘Oncology Brothers.’ He is a valued member of the Guthrie Corning Cancer Center, contributing his extensive knowledge of technology